AR024576A1 - Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatp - Google Patents
Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatpInfo
- Publication number
- AR024576A1 AR024576A1 ARP000103013A ARP000103013A AR024576A1 AR 024576 A1 AR024576 A1 AR 024576A1 AR P000103013 A ARP000103013 A AR P000103013A AR P000103013 A ARP000103013 A AR P000103013A AR 024576 A1 AR024576 A1 AR 024576A1
- Authority
- AR
- Argentina
- Prior art keywords
- increase
- abc1
- methods
- compositions
- cholesterol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
Abstract
La presente invencion se refiere a polipéptidos de ABC1 novedosos y moléculas de ácido nucleico que los codifican. La invencion suministra vectoresrecombinantes, células huésped, y composiciones farmacéuticas que comprenden los polinucleotidos deABC 1, como también a métodos para producir los polipéptidosde ABC1. La invencion además suministra métodos para el diagnostico, tratamiento, mejoramiento y/o prevencion de enfermedades asociadas con un flujo de salidade colesterol disminuido y/oHDL baj o. La presente invencion además suministra métodos para identificar compuestos que modulan la expresion de ABC1 y métodospara detectar el nivel de polipéptidos y polinucleotidos de ABC1 en un sujeto mamífero. La presente invencion ademássuministra e quipos composicionesapropiadas para analizar los compuestos para determinar la actividad que modula la expresion de ABC1 del compuesto, como también los equipos y composicionesapropiados para determinar si el compuesto modula el flujode salida de co lesterol que depende de ABC1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14026499P | 1999-06-18 | 1999-06-18 | |
| US15387299P | 1999-09-14 | 1999-09-14 | |
| US16657399P | 1999-11-19 | 1999-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024576A1 true AR024576A1 (es) | 2002-10-16 |
Family
ID=27385472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000103013A AR024576A1 (es) | 1999-06-18 | 2000-06-16 | Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatp |
| ARP000103012A AR024391A1 (es) | 1999-06-18 | 2000-06-16 | Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une el atp |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000103012A AR024391A1 (es) | 1999-06-18 | 2000-06-16 | Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une el atp |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1190065A2 (es) |
| JP (4) | JP2003508031A (es) |
| KR (2) | KR100476519B1 (es) |
| CN (2) | CN1379817A (es) |
| AR (2) | AR024576A1 (es) |
| AT (1) | ATE422545T1 (es) |
| AU (3) | AU777461B2 (es) |
| BR (2) | BR0011753A (es) |
| CA (2) | CA2375787C (es) |
| DE (1) | DE60041545D1 (es) |
| HK (2) | HK1046427A1 (es) |
| IL (2) | IL147021A0 (es) |
| MX (2) | MXPA01013174A (es) |
| NO (2) | NO20016114L (es) |
| NZ (3) | NZ531401A (es) |
| SG (2) | SG121852A1 (es) |
| TR (2) | TR200200441T2 (es) |
| TW (2) | TWI304737B (es) |
| WO (2) | WO2000078972A2 (es) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1100895T1 (de) | 1999-03-15 | 2001-09-06 | The University Of British Columbia, Vancouver | Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts |
| EP1854880A1 (en) * | 1999-03-15 | 2007-11-14 | University of British Columbia | Methods and reagents for modulating cholesterol levels |
| AU6074700A (en) * | 1999-07-08 | 2001-01-30 | Tularik Inc. | Compositions and methods for raising hdl cholesterol levels |
| WO2001015676A2 (en) * | 1999-09-01 | 2001-03-08 | University Of British Columbia | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| US6555323B2 (en) * | 2000-02-08 | 2003-04-29 | Pfizer Inc. | Assay for ABCA1 |
| NZ522360A (en) | 2000-05-02 | 2004-12-24 | Aventis Pharma Sa | Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses |
| EP1203588A1 (en) * | 2000-11-06 | 2002-05-08 | Bayer Ag | Sterol-independent regulation of ABC1 promoter via oncostatinM |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| AU2002317093A1 (en) * | 2001-07-03 | 2003-01-21 | University Of British Columbia | Screening processes for agents modulating cholesterol levels |
| CA2463395A1 (en) * | 2001-10-12 | 2003-04-24 | Grelan Pharmaceutical Co., Ltd. | Therapeutic agents for low hdl-cholesterolemia |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| WO2003059884A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
| US6696473B2 (en) | 2001-12-21 | 2004-02-24 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| ATE496893T1 (de) | 2002-12-20 | 2011-02-15 | X Ceptor Therapeutics Inc | Isochinolinonderivate und deren verwendung als medikamente |
| RU2006105646A (ru) | 2003-07-23 | 2007-09-10 | Экселиксис, Инк. (Us) | Производные азепина в качестве фармацевтических агентов |
| WO2005116057A1 (en) * | 2004-05-27 | 2005-12-08 | Baker Medical Research Institute | Monoclonal antibody against abca1 |
| EP2172484A3 (en) | 2005-05-18 | 2010-05-19 | Ablynx N.V. | Serum albumin binding proteins |
| CN101213214B (zh) | 2005-05-20 | 2014-06-25 | 埃博灵克斯股份有限公司 | 针对冯威勒布兰特因子的单一结构域vhh抗体 |
| AU2006261845C1 (en) | 2005-06-27 | 2013-05-16 | Exelixis Patent Company Llc | Imidazole based LXR modulators |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| WO2008062830A1 (fr) | 2006-11-24 | 2008-05-29 | Hykes Laboratories Llc | Composé de spiroquinone et composition pharmaceutique |
| EP2514767A1 (en) | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| US20100062004A1 (en) | 2006-12-19 | 2010-03-11 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
| WO2009068625A2 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
| GB2470328A (en) | 2008-03-05 | 2010-11-17 | Ablynx Nv | Novel antigen binding dimer complexes, methods of making and uses thereof |
| US8557965B2 (en) | 2008-04-07 | 2013-10-15 | Ablynx N.V. | Single variable domains against notch pathway members |
| EP2403873A1 (en) | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| ES2610622T3 (es) * | 2009-03-31 | 2017-04-28 | The General Hospital Corporation | Regulación de microARN miR-33 en el tratamiento de trastornos relacionados con colesterol |
| BRPI1013877A2 (pt) | 2009-04-10 | 2017-08-15 | Ablynx Nv | Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r |
| CA2761934C (en) | 2009-05-28 | 2018-01-09 | Exelixis Patent Company Llc | Substituted 1-(biphenyl-4-yl)-2-benzyl-4-hydroxyalkyl-1h-imidazole compounds and their use as lxr modulators |
| WO2011045079A1 (en) | 2009-10-15 | 2011-04-21 | Intercell Ag | Hepatitis b virus specific human antibodies |
| EA037063B1 (ru) | 2010-11-08 | 2021-02-01 | Аблинкс Н.В. | Cxcr2-связывающие полипептиды |
| TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| JP2014525736A (ja) | 2011-06-23 | 2014-10-02 | アブリンクス エン．ヴェー． | ＩｇＥに対する免疫グロブリン単一可変ドメイン |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| WO2013188740A1 (en) | 2012-06-14 | 2013-12-19 | Ambrx, Inc. | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
| US9101745B2 (en) * | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
| US9834542B2 (en) | 2013-03-15 | 2017-12-05 | Bristo-Myers Squibb Company | LXR modulators |
| JP6456909B2 (ja) | 2013-03-15 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｘｒ調節因子 |
| NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| GB201315136D0 (en) * | 2013-08-23 | 2013-10-09 | Univ Glasgow | Cholesterol modulation |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| AU2016360987A1 (en) | 2015-11-27 | 2018-06-07 | Ablynx Nv | Polypeptides inhibiting CD40L |
| EP3512880A1 (en) | 2016-09-15 | 2019-07-24 | Ablynx NV | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
| US11840569B2 (en) | 2016-11-16 | 2023-12-12 | Ablynx N.V. | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta |
| MX2019014504A (es) | 2017-06-02 | 2020-07-20 | Merck Patent Gmbh | Inmunoglobulinas de union a agrecano. |
| TWI825021B (zh) | 2017-06-02 | 2023-12-11 | 德商麥克專利有限公司 | 與ｍｍｐ１３結合之免疫球蛋白 |
| TWI802576B (zh) | 2017-06-02 | 2023-05-21 | 德商馬克專利公司 | 與ａｄａｍｔｓ結合之免疫球蛋白 |
| TW202428621A (zh) | 2017-06-02 | 2024-07-16 | 德商麥克專利有限公司 | 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽 |
| CN115433733A (zh) | 2021-06-04 | 2022-12-06 | 生物岛实验室 | 环状RNA Circ-ACE2翻译的多肽及其应用 |
| CN114369162B (zh) | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| WO2024023271A1 (en) | 2022-07-27 | 2024-02-01 | Ablynx Nv | Polypeptides binding to a specific epitope of the neonatal fc receptor |
| WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
| WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ522360A (en) * | 2000-05-02 | 2004-12-24 | Aventis Pharma Sa | Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses |
-
2000
- 2000-06-16 AU AU57467/00A patent/AU777461B2/en not_active Ceased
- 2000-06-16 CA CA002375787A patent/CA2375787C/en not_active Expired - Fee Related
- 2000-06-16 CN CN00809163A patent/CN1379817A/zh active Pending
- 2000-06-16 EP EP00942867A patent/EP1190065A2/en not_active Withdrawn
- 2000-06-16 AR ARP000103013A patent/AR024576A1/es unknown
- 2000-06-16 AU AU57434/00A patent/AU5743400A/en not_active Abandoned
- 2000-06-16 JP JP2001515880A patent/JP2003508031A/ja active Pending
- 2000-06-16 DE DE60041545T patent/DE60041545D1/de not_active Expired - Fee Related
- 2000-06-16 WO PCT/US2000/016765 patent/WO2000078972A2/en not_active Application Discontinuation
- 2000-06-16 SG SG200307655A patent/SG121852A1/en unknown
- 2000-06-16 NZ NZ531401A patent/NZ531401A/en unknown
- 2000-06-16 CA CA002375781A patent/CA2375781A1/en not_active Abandoned
- 2000-06-16 KR KR10-2001-7016284A patent/KR100476519B1/ko not_active IP Right Cessation
- 2000-06-16 TR TR2002/00441T patent/TR200200441T2/xx unknown
- 2000-06-16 BR BR0011753-6A patent/BR0011753A/pt not_active Application Discontinuation
- 2000-06-16 AR ARP000103012A patent/AR024391A1/es unknown
- 2000-06-16 MX MXPA01013174A patent/MXPA01013174A/es unknown
- 2000-06-16 BR BR0011696-3A patent/BR0011696A/pt not_active IP Right Cessation
- 2000-06-16 MX MXPA01013175A patent/MXPA01013175A/es active IP Right Grant
- 2000-06-16 IL IL14702100A patent/IL147021A0/xx unknown
- 2000-06-16 AT AT00942914T patent/ATE422545T1/de not_active IP Right Cessation
- 2000-06-16 IL IL14702200A patent/IL147022A0/xx unknown
- 2000-06-16 TR TR2002/00440T patent/TR200200440T2/xx unknown
- 2000-06-16 JP JP2001515881A patent/JP2003506097A/ja active Pending
- 2000-06-16 KR KR1020017016286A patent/KR20020012612A/ko not_active Application Discontinuation
- 2000-06-16 SG SG200307656A patent/SG121853A1/en unknown
- 2000-06-16 EP EP00942914A patent/EP1218515B1/en not_active Expired - Lifetime
- 2000-06-16 NZ NZ516061A patent/NZ516061A/en unknown
- 2000-06-16 WO PCT/US2000/016591 patent/WO2000078971A2/en not_active Application Discontinuation
- 2000-06-16 NZ NZ529785A patent/NZ529785A/en unknown
- 2000-06-16 CN CNB008091641A patent/CN100513570C/zh not_active Expired - Fee Related
- 2000-08-25 TW TW095113205A patent/TWI304737B/zh active
- 2000-08-25 TW TW089111924A patent/TWI259205B/zh not_active IP Right Cessation
-
2001
- 2001-12-14 NO NO20016114A patent/NO20016114L/no unknown
- 2001-12-14 NO NO20016121A patent/NO20016121L/no not_active Application Discontinuation
-
2002
- 2002-09-26 HK HK02107131.3A patent/HK1046427A1/zh unknown
- 2002-11-13 HK HK02108234.7A patent/HK1046708A1/zh unknown
-
2004
- 2004-11-04 JP JP2004320358A patent/JP4277956B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-14 AU AU2005200171A patent/AU2005200171A1/en not_active Abandoned
- 2005-10-26 JP JP2005311515A patent/JP2006137750A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024576A1 (es) | Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatp | |
| BRPI0315666B8 (pt) | dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos | |
| TR200003159T2 (tr) | Antipicornaviral bileşikler, hazırlanışları ve kullanımları | |
| ES2526912T3 (es) | Composición farmacéutica que contiene neurotoxina botulínica A2 | |
| DK1666052T3 (da) | Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer | |
| BRPI0507026A (pt) | proteìnas de fusão de albumina | |
| BR0009537A (pt) | Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso | |
| EA200200105A1 (ru) | СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ; | |
| TR200100149T2 (tr) | Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler | |
| CY1112845T1 (el) | Παραγωγα της 1-δεοξυ-γαλακτονογιριμυκινης και η χρηση τους στη θεραπεια αθροιστικων λυσοσωμικων ασθενειων μεσω ενισχυσης της λυσοσωμικης α-γαλακτοσιδασης α | |
| BR9912007A (pt) | Composições e métodos para terapia e diagnóstico de câncer de próstata | |
| WO2004031411A3 (en) | Genes and polypeptides relating to human pancreatic cancers | |
| AU9779498A (en) | Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor | |
| AR026946A1 (es) | Osteoprotegerina/receptores de factores de necrosis de tumores | |
| PT1143955E (pt) | Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete | |
| Idkowiak-Baldys et al. | Growth differentiation factor 11 (GDF11) has pronounced effects on skin biology | |
| DE69830251D1 (de) | Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen | |
| MY157947A (en) | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity | |
| TR200103339T2 (tr) | Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri. | |
| ES2131612T3 (es) | Oligomeros de union a acidos nucleicos con ramificacion en c para terapia y diagnostico. | |
| Bradford et al. | Contiguous binding and inhibitory sites on kininogens required for the inhibition of platelet calpain. | |
| ATE396403T1 (de) | Verwendung des urokinase plasminogen aktivator rezeptors als zielscheibe in der diagnose von micrometastasen | |
| ATE404865T1 (de) | T zell-subpopulation zur regelung der darmimmunität | |
| ES2130629T3 (es) | Compuestos peptidicos de proinsulina para detectar y tratar la diabetes tipo i. | |
| ATE236983T1 (de) | Durch zelldichte stimulierte protein-tyrosin- phosphatasen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |